Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2021
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Purdue Pharma
- 01 Jul 2021 Results published in an Adlon Therapeutics L.P Media Release.
- 01 Jul 2021 Primary endpoint (Change in PERMP-T (Permanent Measure of Productivity (Total Score)).) has been met, according to a Adlon Therapeutics L.P media release.
- 01 Jul 2021 According to an Adlon Therapeutics L.P media release, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the prescribing information for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, based on data from this trial.